Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib With or Without Sildenafil for Brain Tumors
NCT07039760Phase 1Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of asciminib in brain tumor (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Tumor:plasma ratio of asciminib at Day 1 and Tumor:plasma ratio of asciminib with sildenafil at Day 1. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT07039760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039760.